[go: up one dir, main page]

AR037756A1 - Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. - Google Patents

Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.

Info

Publication number
AR037756A1
AR037756A1 ARP020104759A ARP020104759A AR037756A1 AR 037756 A1 AR037756 A1 AR 037756A1 AR P020104759 A ARP020104759 A AR P020104759A AR P020104759 A ARP020104759 A AR P020104759A AR 037756 A1 AR037756 A1 AR 037756A1
Authority
AR
Argentina
Prior art keywords
cell factor
asthma
activity
treatment
precursor cell
Prior art date
Application number
ARP020104759A
Other languages
English (en)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR037756A1 publication Critical patent/AR037756A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee de anticuerpos humanos específicos para el factor de las células precursoras que contienen por lo menos una CDR derivada de una biblioteca combinatoria de anticuerpos. La presemte provee, además, de composiciones farmacéuticas que comprenden los anticuerpos y métodos para tratar el asma. La presente provee, en forma adicional, de métodos para detectar el factor de las células huésped usando los anticuerpos.
ARP020104759A 2001-12-17 2002-12-09 Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. AR037756A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34217401P 2001-12-17 2001-12-17

Publications (1)

Publication Number Publication Date
AR037756A1 true AR037756A1 (es) 2004-12-01

Family

ID=23340685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104759A AR037756A1 (es) 2001-12-17 2002-12-09 Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.

Country Status (8)

Country Link
US (2) US7285640B2 (es)
AR (1) AR037756A1 (es)
AU (1) AU2002361720A1 (es)
GT (1) GT200200279A (es)
HN (1) HN2002000366A (es)
TW (1) TW200305435A (es)
UY (1) UY27583A1 (es)
WO (1) WO2003051311A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
WO2006002064A2 (en) * 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
WO2007056441A2 (en) * 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
RU2540150C2 (ru) * 2007-06-25 2015-02-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009135001A2 (en) * 2008-04-30 2009-11-05 University Of Pittsburgh- Commonwealth System Of Higher Education Methods and compositions for regulating th2 and th17 responses
EP2352758A2 (en) * 2008-09-26 2011-08-10 Wyeth LLC Single chain antibody library design
US8911729B2 (en) 2011-01-10 2014-12-16 The Regents Of The University Of Michigan Stem cell factor inhibitor
KR101384360B1 (ko) * 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
KR20220079561A (ko) * 2019-09-16 2022-06-13 옵시디오, 엘엘씨 항-줄기세포 인자 항체 및 이의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US6187559B1 (en) * 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
US6576812B1 (en) * 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
WO2001092543A2 (en) * 2000-05-30 2001-12-06 Ich Productions Limited Improved methods of transfection
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.

Also Published As

Publication number Publication date
GT200200279A (es) 2003-07-18
TW200305435A (en) 2003-11-01
US7285640B2 (en) 2007-10-23
US20050112698A1 (en) 2005-05-26
AU2002361720A1 (en) 2003-06-30
US20030194405A1 (en) 2003-10-16
AU2002361720A8 (en) 2003-06-30
WO2003051311A3 (en) 2004-09-30
HN2002000366A (es) 2003-04-21
WO2003051311A2 (en) 2003-06-26
UY27583A1 (es) 2003-06-30

Similar Documents

Publication Publication Date Title
Virard et al. Cold atmospheric plasma induces a predominantly necrotic cell death via the microenvironment
AR037756A1 (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
UY28342A1 (es) Nuevos compuestos
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
EA200501586A1 (ru) Фармацевтические продукты
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
NO20081636L (no) FAP - inhibitorer
ECSP055525A (es) Inhibidores de cinasas de tirosina
DE60314623D1 (de) Substituierte pyrazolopyrimidine
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2008003366A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados, inhibidores de proteinas quinasas mek y mapk/erk; proceso de preparacion de los compuestos; composicion farmaceutica que los comprende; conjunto que los comprende; y su uso en la preparacion de medicamentos para el tratamiento de trastornos hiperproliferativos.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
UY28348A1 (es) Compuestos novedosos
ATE482693T1 (de) Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
NO20072290L (no) Organiske forbindelser.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
UY28731A1 (es) Compuestos quimicos
BRPI0517035A (pt) novos compostos

Legal Events

Date Code Title Description
FB Suspension of granting procedure